LivaNova (NASDAQ:LIVN) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of LivaNova (NASDAQ:LIVN) in a research report sent to investors on Monday morning, Analyst Ratings Network reports.

LIVN has been the topic of a number of other research reports. TheStreet upgraded shares of LivaNova from a d+ rating to a c- rating in a research report on Tuesday, February 23rd. Piper Sandler dropped their target price on shares of LivaNova from $99.00 to $98.00 and set an overweight rating on the stock in a research report on Tuesday, June 1st. Robert W. Baird boosted their target price on shares of LivaNova from $85.00 to $100.00 and gave the company an outperform rating in a research report on Thursday, April 29th. Berenberg Bank reiterated a hold rating and set a $84.00 target price on shares of LivaNova in a research report on Tuesday, March 9th. Finally, Zacks Investment Research downgraded shares of LivaNova from a hold rating to a sell rating in a research report on Tuesday, May 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $87.50.

LIVN opened at $81.22 on Monday. LivaNova has a fifty-two week low of $41.07 and a fifty-two week high of $90.25. The company has a quick ratio of 1.92, a current ratio of 2.34 and a debt-to-equity ratio of 0.61. The company has a market cap of $3.97 billion, a price-to-earnings ratio of -9.59 and a beta of 0.89. The stock’s 50 day simple moving average is $81.91.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, April 28th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.20. The firm had revenue of $247.60 million for the quarter, compared to the consensus estimate of $232.30 million. LivaNova had a negative net margin of 43.88% and a positive return on equity of 5.21%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.33 EPS. As a group, research analysts expect that LivaNova will post 1.46 EPS for the current fiscal year.

In other LivaNova news, SVP Marco Dolci sold 8,278 shares of the business’s stock in a transaction on Tuesday, May 18th. The shares were sold at an average price of $82.91, for a total transaction of $686,328.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.37% of the company’s stock.

A number of hedge funds have recently made changes to their positions in LIVN. Strs Ohio increased its stake in LivaNova by 66.7% during the 4th quarter. Strs Ohio now owns 2,500 shares of the company’s stock valued at $165,000 after purchasing an additional 1,000 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of LivaNova by 10.9% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,105 shares of the company’s stock worth $338,000 after acquiring an additional 500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of LivaNova by 11.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,801 shares of the company’s stock worth $450,000 after acquiring an additional 707 shares in the last quarter. California Public Employees Retirement System grew its stake in shares of LivaNova by 1.0% in the 4th quarter. California Public Employees Retirement System now owns 104,632 shares of the company’s stock worth $6,928,000 after acquiring an additional 1,078 shares in the last quarter. Finally, State of Wisconsin Investment Board grew its stake in shares of LivaNova by 687.1% in the 4th quarter. State of Wisconsin Investment Board now owns 616,337 shares of the company’s stock worth $40,808,000 after acquiring an additional 538,037 shares in the last quarter. Institutional investors and hedge funds own 93.58% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

Further Reading: Market Capitalization

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.